Slc13a3-KO Mouse
Common Name
Slc13a3-KO
제품 ID
S-KO-19083
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-114644-Slc13a3-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Slc13a3-KO Mouse (카탈로그 번호 S-KO-19083)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Slc13a3-KO
품종 계통계통 ID
KOCMP-114644-Slc13a3-B6J-VB
유전자명
제품 ID
S-KO-19083
유전자 별칭
NaC3, NaDC3, SDCT2, NaDC-3
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 2
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000029208
NCBI 전사체 ID
NM_054055
타겟 영역
Exon 3
유효 영역 크기
~1.3 kb
유전자 연구 개요
Slc13a3, encoding the plasma membrane Na+/dicarboxylate cotransporter 3 (NaDC3), is mainly expressed in the kidney, astrocytes, and choroid plexus. It imports 4-6 carbon dicarboxylates and N-acetylaspartate (NAA) into the cell, playing important roles in multiple biological processes and associated with various pathways [5,7].
In cancer research, gene-targeted mouse models have provided valuable insights. In liver cancer, activation of β-catenin up-regulates Slc13a3, and its silencing in β-catenin-activated liver cancer cells leads to leucine depletion, mTOR inactivation, GSH depletion, and autophagic ferroptosis. Both genetic inhibition of Slc13a3 and a small molecule inhibitor suppress β-catenin-driven hepatocarcinogenesis in mice, suggesting it as a therapeutic target for liver cancers with GOF CTNNB1 mutations [2].
In the tumor microenvironment, deletion of Slc13a3 in tumors or treatment with its inhibitor sensitizes tumors to ferroptosis, curbs tumor progression, and enhances immune checkpoint blockade (ICB) effectiveness as tumor cells uptake itaconate via Slc13a3 from tumor-associated macrophages (TAMs), activating the NRF2-SLC7A11 pathway to escape immune-mediated ferroptosis [1]. Also, Slc13a3 inhibition enhances the efficacy of anti-CTLA-4 immunotherapy in syngeneic mouse tumor models as itaconate transported by Slc13a3 alkylates PD-L1, stabilizing it and promoting tumor immune evasion [4].
In hepatic antibacterial innate immunity, liver-specific deletion of Slc13a3 impairs this immunity both in vivo and in vitro. Itaconate uptake via Slc13a3 induces TFEB-dependent lysosomal biogenesis to improve antibacterial innate immunity in mouse hepatocytes [3].
In Canavan leukodystrophy murine models, astroglial conditional Slc13a3 knockout reversed brain NAA elevation and improved motor function [6].
In conclusion, Slc13a3 is crucial for the transport of specific molecules and is involved in multiple biological processes. Studies using gene knockout or conditional knockout mouse models have revealed its significance in diseases such as cancer, hepatic antibacterial immunity, and Canavan leukodystrophy. These findings provide potential therapeutic targets and new insights into the pathogenesis of these diseases.
References:
1. Lin, Heng, Tison, Kole, Du, Yuheng, Wang, Shaomeng, Zou, Weiping. 2024. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. In Cancer cell, 42, 2032-2044.e6. doi:10.1016/j.ccell.2024.10.010. https://pubmed.ncbi.nlm.nih.gov/39515327/
2. Zhao, Wennan, Wang, Xue, Han, Lifeng, Chen, Xin, Zhang, Youcai. 2024. SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis. In Nature communications, 15, 7522. doi:10.1038/s41467-024-51860-2. https://pubmed.ncbi.nlm.nih.gov/39215042/
3. Chen, Chao, Liu, Caiyun, Sun, Pengkai, Liu, Ping, Li, Xinjian. 2024. Itaconate uptake via SLC13A3 improves hepatic antibacterial innate immunity. In Developmental cell, 59, 2807-2817.e8. doi:10.1016/j.devcel.2024.07.011. https://pubmed.ncbi.nlm.nih.gov/39116875/
4. Fan, Yizeng, Dan, Weichao, Wang, Yuzhao, Wei, Wenyi, Li, Lei. 2025. Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. In Cell metabolism, 37, 514-526.e5. doi:10.1016/j.cmet.2024.11.012. https://pubmed.ncbi.nlm.nih.gov/39809284/
5. Dewulf, Joseph P, Wiame, Elsa, Dorboz, Imen, Nassogne, Marie-Cécile, Schiff, Manuel. 2019. SLC13A3 variants cause acute reversible leukoencephalopathy and α-ketoglutarate accumulation. In Annals of neurology, 85, 385-395. doi:10.1002/ana.25412. https://pubmed.ncbi.nlm.nih.gov/30635937/
6. Hull, Vanessa L, Wang, Yan, McDonough, Jennifer, Guo, Fuzheng, Pleasure, David. 2024. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy. In Annals of clinical and translational neurology, 11, 1059-1062. doi:10.1002/acn3.52010. https://pubmed.ncbi.nlm.nih.gov/38282243/
7. Hussain, Syeda Iqra, Muhammad, Nazif, Shah, Salah Ud Din, Wasif, Naveed, Khan, Saadullah. 2023. Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability. In BMC neurology, 23, 353. doi:10.1186/s12883-023-03397-y. https://pubmed.ncbi.nlm.nih.gov/37794328/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
